Impax Asset Management Group plc purchased a new position in Revvity, Inc. (NYSE:RVTY - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 83,753 shares of the company's stock, valued at approximately $9,155,000. Impax Asset Management Group plc owned 0.07% of Revvity at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of the stock. Gladius Capital Management LP increased its stake in Revvity by 84.1% in the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company's stock worth $26,000 after purchasing an additional 106 shares during the period. CENTRAL TRUST Co bought a new stake in shares of Revvity in the 4th quarter worth approximately $27,000. JTC Employer Solutions Trustee Ltd bought a new stake in shares of Revvity in the 4th quarter worth approximately $33,000. Headinvest LLC bought a new stake in shares of Revvity in the 3rd quarter worth approximately $57,000. Finally, DB Wealth Management Group LLC bought a new stake in shares of Revvity in the 4th quarter worth approximately $79,000. 86.65% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of Revvity stock in a transaction on Monday, February 5th. The stock was sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the completion of the sale, the insider now directly owns 92,801 shares of the company's stock, valued at approximately $9,677,288.28. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.60% of the stock is owned by corporate insiders.
Revvity Price Performance
NYSE RVTY traded up $0.64 during trading on Thursday, hitting $108.54. 2,903,814 shares of the stock traded hands, compared to its average volume of 856,615. The company has a market capitalization of $13.41 billion, a P/E ratio of 19.62, a price-to-earnings-growth ratio of 2.77 and a beta of 1.09. The firm has a 50-day simple moving average of $105.13 and a 200-day simple moving average of $101.95. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. Revvity, Inc. has a 12-month low of $79.50 and a 12-month high of $139.04.
Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Thursday, February 1st. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.15 by $0.10. Revvity had a return on equity of 7.41% and a net margin of 25.20%. The firm had revenue of $695.90 million during the quarter. As a group, analysts predict that Revvity, Inc. will post 4.65 EPS for the current year.
Revvity Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date of this dividend is Thursday, April 18th. Revvity's dividend payout ratio is currently 5.09%.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the company. KeyCorp lifted their price objective on Revvity from $110.00 to $126.00 and gave the stock an "overweight" rating in a research report on Friday, February 2nd. Barclays upped their price target on Revvity from $92.00 to $105.00 and gave the company an "equal weight" rating in a report on Thursday, January 25th. Raymond James upped their price target on Revvity from $106.00 to $127.00 and gave the company an "outperform" rating in a report on Friday, February 2nd. Wolfe Research began coverage on Revvity in a report on Wednesday, December 13th. They issued a "peer perform" rating on the stock. Finally, UBS Group downgraded Revvity from a "buy" rating to a "neutral" rating and increased their target price for the company from $105.00 to $125.00 in a report on Tuesday, January 16th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $118.91.
Check Out Our Latest Stock Report on Revvity
About Revvity
(
Free Report)
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Featured Articles
Before you consider Revvity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.
While Revvity currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
